A recent complaint filed by plaintiff Jerold Lamhut on June 14, in the US District Court of New Jersey, indicated that he received contaminated valsartan pills for years which contained known human carcinogens which were a byproduct of the drug manufacturing process which resulted in the diagnosis of bladder cancer.
The lawsuits named different generic drugmakers as defendants like Zhejiang Huahai Pharmaceutical, Princeton Pharmaceutical, Solco Healthcare US, Aurobindo Pharma, Walmart, and 100 other unidentified companies. The plaintiff indicated that he received various different generic valsartan pills between May 2015 and May 2018 which were discovered to be contaminated with Nitroso-dimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), or other nitrosamine compounds that are known to increase the risk of cancer.
Since July 2018, a series of generic valsartan recalls have been issued by different manufacturers due to the presence of NDMA and NDEA, which had contaminated much of the U.S. supply of the hypertension drug distributed in recent years. A number of generic valsartan lawsuits were filed in recent months by individuals who indicated that they were left with a number of other types of cancer, including liver cancer, kidney cancer, gastric cancer, pancreatic cancer, and other injuries following exposure to NDMA or NDEA.